INTRODUCTION

GlycA is a novel biomarker of inflammation that has been associated with a variety of outcomes in rheumatoid arthritis (RA) and other diseases. In previous studies, serum levels of glycated acute phase proteins, such as fibrinogen, have been found to be higher in patients with RA compared to healthy controls. These findings suggest that glycated proteins may play a role in the inflammatory response associated with RA.

The objective of this analysis was to assess changes in GlycA levels in the Phase 2 JADA and Phase 3 RA-BEAM studies in patients with RA treated with baricitinib.

RESULTS

Table 2. Phase 1A JADA Study: Baseline Characteristics and Disease Activity

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Baseline</th>
<th>1 Week</th>
<th>2 Weeks</th>
<th>4 Weeks</th>
<th>8 Weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>53 (17)</td>
<td>53 (17)</td>
<td>53 (17)</td>
<td>53 (17)</td>
<td>53 (17)</td>
</tr>
<tr>
<td>RF positive, n (%)</td>
<td>64 (65)</td>
<td>64 (65)</td>
<td>64 (65)</td>
<td>64 (65)</td>
<td>64 (65)</td>
</tr>
<tr>
<td>ACPA positive, n (%)</td>
<td>61 (62)</td>
<td>61 (62)</td>
<td>61 (62)</td>
<td>61 (62)</td>
<td>61 (62)</td>
</tr>
<tr>
<td>ESR, mm/h</td>
<td>49 (26.1)</td>
<td>49 (26.1)</td>
<td>49 (26.1)</td>
<td>49 (26.1)</td>
<td>49 (26.1)</td>
</tr>
<tr>
<td>Tender joint count, of 68</td>
<td>22.2 (12.1)</td>
<td>22.2 (12.1)</td>
<td>22.2 (12.1)</td>
<td>22.2 (12.1)</td>
<td>22.2 (12.1)</td>
</tr>
</tbody>
</table>

Table 3. Change in Lipid and GlycA Levels from Baseline to Week 12 According to Baseline Statin Use in the Phase 3 RA-BEAM Study

<table>
<thead>
<tr>
<th>Statin Use</th>
<th>Change in GlycA levels, µmol/L</th>
<th>Change in LDL cholesterol, mg/dL</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>-14.3 (14.1)</td>
<td>-2.2 (1.1)</td>
</tr>
<tr>
<td>Yes</td>
<td>-14.3 (14.1)</td>
<td>-2.2 (1.1)</td>
</tr>
</tbody>
</table>

CONCLUSIONS

- Treatment with baricitinib resulted in dose-dependent decreases in GlycA levels from baseline to Week 12 in the Phase 2 study (P=0.005 vs adalimumab) and the Phase 3 study (P<0.001 vs placebo).
- There were similar reductions in GlycA with baricitinib regardless of baseline statin use (Table 3).

ACKNOWLEDGMENTS

This study was supported by Eli Lilly and Company, AbbVie, Pfizer, Novartis, Roche, Janssen, and Pfizer.

REFERENCES


Author Information

- Eli Lilly and Company
- AbbVie
- Pfizer
- Novartis
- Roche
- Janssen
- Pfizer

#415

American College of Rheumatology (ACR) 2017 Annual Scientific Meeting, San Diego, CA USA, November 3-8, 2017

Sponsored by Eli Lilly and Company and Incyte Corporation